KBirb on Twitter: Tweets 1 - 16 [READ THRU END, #16] … @richardursomd @PierreKory @drsimonegold https://t.co/EcYjRQ4ksk" / Twitter
1) AFRICA & IVE*MECTIN According to study (in thread), 31 countries (I marked in blue) have had regular dispensing/access to Ive*mectin. The others have not. A dramatic difference. Starting with daily deaths/100k. [READ THRU END, #15] …
2) AFRICA & IVE*MECTIN. …and the case curves. …
KBirb
3) AFRICA & IVE*MECTIN. Ive*mectin group: 31 countries, total pop 972.5 million. Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo (Brazzaville), Congo (Kinshasa), Cote d'Ivoire, Equatorial Guinea, Ethiopia, Gabon, Ghana, Guinea…
KBirb
@birb_k
·
Aug 274) AFRICA & IVE*MECTIN. Ive*mectin group (continued): …Guinea-Bissau, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Rwanda, Senegal, Sierra Leone, South Sudan, Sudan, Tanzania, Togo, Uganda. …
5) AFRICA & IVE*MECTIN. Non-Ive*mectin group: 22 countries, total pop 357.3 million. Algeria, Botswana, Cabo Verde, Comoros, Egypt, Eritrea, Eswatini, Gambia, Lesotho, Libya, Madagascar, Mauritania, Mauritius, Morocco, Namibia, Sao Tome and Principe, Seychelles, Somalia…
KBirb
@birb_k
Replying to
6) AFRICA & IVE*MECTIN. Non-Ive*mectin group (continued): …South Africa, Tunisia, Zambia, Zimbabwe. …
KBirb
@birb_k
8) AFRICA & IVE*MECTIN. How did the 31 countries gain access to Ive*mectin? You may have heard of River Blindness (Onchocerciasis). “Treatment for onchocerciasis is ivermectin (trade name: Mectizan).” This is widely celebrated as a huge medical success story. …
9) AFRICA & IVE*MECTIN. Onchocerciasis is prevalent in Sub-Saharan Africa. General information available here, or you can search deeper if interested. The key is that the identified countries have regular and widespread access and use of Ive*mectin. https://en.wikipedia.org/wiki/Onchocerciasis… …
Onchocerciasis - Wikipedia
en.wikipedia.org
10) AFRICA & IVE*MECTIN. Japanese study in Q1 2021 goes into more details on the Africa countries involved, including the list of countries I used in this thread, and to get the Johns Hopkins data shown up front (deaths & cases). Study preprint, below. … https://medrxiv.org/content/10.1101/2021.03.26.21254377v1.full.pdf…
11) AFRICA & IVE*MECTIN. Many have seen the viral Feb 2021 video of Haruo Ozaki, Chairman of the Tokyo Medical Association making a recommendation to Japan’s health minister for off-label use of Ive*mectin based on data from the Japanese study highlighting the Africa success. …
Dr. Simone Gold@drsimonegold· Aug 26The house of corona-cards is crumbling. We’ve been telling everyone willing to listen for over a YEAR that early treatment works. Turns out…we were right. twitter.com/fonzydizzle/s
12) AFRICA & IVE*MECTIN. From Ozaki’s press briefing video (based on data from study), some astonishing statistics, summarized in two graphs I created. First, a comparison of CASES/100K between the IVM & non-IVM groups, a 7.1-fold difference. …
KBirb
13) AFRICA & IVE*MECTIN. …Second, a comparison of DEATHS/100K between IVM & non-IVM groups, a massive 13.3-fold difference. These data (cases and deaths) align with the findings from the more up-to-date data out of Johns Hopkins CSSE, the first two pages of this thread. …
14) AFRICA & IVE*MECTIN. Next logical question - what is the va*x rate difference between the two groups? This may surprise some. The IVM group is far less va**inated than the non-IVM group, so we see an inverse relationship. IVM seems to be the overwhelming, obvious factor.
15) AFRICA & IVE*MECTIN. PROLOGUE. Did Japan’s Health Minister authorize the use of Ive*mectin based on the compelling data and plea from Ozaki, chief of Tokyo Medical Association? From my research I think the answer is NO. Sound familiar? Please correct me if I’m wrong. (end)
16) AFRICA & IVE*MECTIN. ADDENDUM. The Japan study included data snapshot thru 1/15/21. The charts I created pick up additional data thru 8/25/20, including an entirely new major surge. The curves for Ive*mectin group remain modest thru the period, adding observational strength.
